MAYBAKER - May & Baker Nigeria
Manufacturing and Distribution of Pharmaceutical and Consumer goods
May & Baker Nigeria is listed on the Nigerian Stock Exchange (NGX) since November 10th, 1994. May & Baker is traded on the NGX under the ticker symbol “MAYBAKER”. The International Securities Identification Number (ISIN) of NGX:MAYBAKER is NGMAYBAKER01. May & Baker Nigeria is currently the 75th most valuable stock on the NGX with a market capitalization of NGN 8.88 billion, which makes about 0.025% of the Nigerian Stock Exchange equity market.
|Last Trading Results|
|Day’s Low Price|
|Day’s High Price|
|Number of Deals||14|
|Growth & Valuation|
|Earnings Per Share|
|Dividend Per Share|
MAYBAKER Stock Market Performance
The current share price of May & Baker Nigeria (MAYBAKER) is NGN 5.15. MAYBAKER closed its last trading day (Friday, September 29, 2023) at 5.15 NGN per share on the Nigerian Stock Exchange (NGX). May & Baker began the year with a share price of 4.30 NGN and has since gained 19.8% on that price valuation, ranking it 89th on the NGX in terms of year-to-date performance.
May & Baker Nigeria is the 81st most traded stock on the Nigerian Stock Exchange over the past three months (Jul 4 - Sep 29, 2023). MAYBAKER has traded a total volume of 28.7 million shares—in 1,815 deals—valued at NGN 150 million over the period, with an average of 455,080 traded shares per session. A volume high of 1.77 million was achieved on August 8th, and a low of 4,369 on July 13th, for the same period. The table below details the last 10 trading days of activity of May & Baker Nigeria on the Nigerian Stock Exchange.
Profile of May & Baker Nigeria
May & Baker Nigeria operates in the Health Care sector.
Factsheet of May & Baker Nigeria
- Health Care
- 3/5 Sapara Street, Industrial Estate, Ikeja, Lagos
MAYBAKER Industrial Market Competitors
May & Baker Nigeria, issuers of the MAYBAKER stock on the Nigerian Stock Exchange, have six market competitors who are also engaged in the Health Care sector. The table below presents an overview of their market standing.
|GLAXOSMITH||Glaxo Smithkline Consumer||13.6B||11.35||+84.6%|
|NEIMETH||Neimeth International Pharma||7.18B||1.68||+17.5%|